Liver metabolism is commonly considered the major determinant in drug discovery and development. Many in vitro drug metabolic studies have been developed and applied to understand biotransformation. However, these methods have disadvantages, resulting in inconsistencies between in vivo and in vitro experiments. A major factor is that they are static systems that do not consider the transport process in the liver. Here we developed an in vitro dynamic metabolic system (Bio-PK metabolic system) to mimic the human pharmacokinetics of tolbutamide. Human liver microsomes (HLMs) encapsulated in a F127'-Acr-Bis hydrogel (FAB hydrogel) were placed in the incubation system. A microdialysis sampling technique was used to monitor the metabolic behavior of tolbutamide in in vitro intrinsic clearance of tolbutamide with a mathematical model. Then, a PBPK model that integrated the corresponding in vitro intrinsic clearance was developed to verify the system. in vivo clearance of tolbutamide could be predicted by integrating the intrinsic clearance of tolbutamide obtained from the Bio-PK metabolic system into the PBPK model. The predicted maximum concentration (C max ), area under the concentration-time curve (AUC), time to reach the maximum plasma concentration (T max ) and in vivo clearance were consistent with the clinically observed data. This novel in vitro dynamic metabolic system can compensate for some limitations of traditional incubation methods; it may provide a new method for screening compounds and predicting pharmacokinetics in the early stages, supporting the development of compounds.
Introduction
In vitro studies of drugs are usually prioritized over in vivo ones, especially in humans. In the early stages of drug discovery and development, in vitro data can be used not only to rapidly screen compounds but also to understand the mechanisms and guide the further study of drugs and decisionmaking [1, 2] . The liver plays an important role in the human body, involving the metabolism and elimination of drugs [3, 4] . Metabolites may have more activity or toxicity than the parent drug, [5] [6] [7] . Thus, biotransformation in the liver is a determinant in the overall disposition of drugs. A reliable in vitro metabolic system to predict metabolic behavior in the human body is highly desired.
Currently, many in vitro metabolic systems have been developed to explain hepatic extraction. Kinetic parameters, such as V max and K m , can be determined in vitro using hepatocytes, microsomes, cytoplasm, the S-9 fraction or liver slices extracted from the liver of humans and other laboratory animals [8] [9] [10] [11] . The intrinsic clearance (CL int =V max /K m under linear conditions) obtained from these models can be converted to in vivo intrinsic clearance using various scaling methods, based on the amount of enzyme present in vivo [12] . However, these systems have several limitations, such as a scarce and inconsistent metabolic rate. As the gold standard, hepatocytes are prone to inactivation over time in culture. Moreover, available primary human hepatocytes are fewer in number and scarce, as they are mainly derived from poor-quality or poorly transplanted substances [13] [14] [15] . The incubation time for microsomes and recombinases is often short, which limits the generation clearance rate [16] [17] [18] . More importantly, the systems described above are static, simplifying the circulation processes occurring in the liver [19] . To better understand the metabolic behavior, a new in vitro metabolic system must be developed.
In our previous study, a hydrogel carrier (F127-acrylamidebisacrylamide, FAB hydrogel) with a polymer thermosensitive material was invented. FAB hydrogel is a reverse-phase hydrogel, with the appropriate proportion of hydrogel presenting a loose, porous three-dimensional structure suitable for liver microsomal loading. It has been confirmed that microsomes encapsulated in hydrogel still have good metabolic activity [20] . Compared to ordinary microsomes, microsomal hydrogels can be used for long-term incubation reactions due to their ability to maintain longer metabolic activity and metabolic turnover [20] . We have further developed an in vitro dynamic metabolic cycle system (Bio-PK system) to better mimic and understand the metabolic behavior. Rat liver microsomes encapsulated in a FAB hydrogel were combined with the Bio-PK system, which successfully predicted the in vivo metabolism of tolbutamide [21] . A dynamic bio-pharmacokinetic/pharmacodynamic (PK/PD) system was established and assessed to predict the PK parameters and PD effects of the model drug cyclophosphamide [22] . However, drug research in humans is the ultimate goal of drug development. Due to differences in species, it is desirable to estimate clearance in humans. Based on the above results, it is important to further apply the Bio-PK system combined with microsomal hydrogel to predict human metabolism.
The objectives of the present work are 1) to prepare a microsomal hydrogel that can encapsulate human liver microsomes; 2) to construct the Bio-PK system to obtain the in vitro intrinsic clearance of tolbutamide; 3) to build the PBPK model via integration with the in vitro intrinsic clearance obtained from the Bio-PK system to predict the clinically pharmacokinetics of tolbutamide; and, ultimately, 4) to evaluate the potential and reliability of this system in predicting human metabolic behavior and to support the further development of the system.
Materials and methods

Chemicals and reagents
Pluronic F-127, tolbutamide, and 4-hydroxytolbutamide were purchased from Sigma Aldrich (St Louis, MO, USA). The BCA Protein Assay Kit, 30% Acr-Bis (29:1), ammonium persulfate (APS), and N,N,N',N'-tetramethylethylenediamine (TEMED) were obtained from the Beyotime Institute of Biotechnology (Nanjing, China). Phenacetin was acquired from Aladdin (Shanghai, China). Mixed gender pooled human liver microsomes (prepared from at least 20 donors) were obtained from Corning Life Sciences (Tewksbury, MA, USA), and was acquired from Roche (Mannheim, Germany).
HPLC-grade methanol was purchased from TEDIA Com-Q water system (Bedford, MA, USA , and 0.1 mmol/L ascorbic acid, pH 7.0) and phosphate buffer saline (PBS) solution (137 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L sodium phosphate dibasic, and 2 mmol/L potassium phosphate monobasic, pH 7.4) were prepared in our laboratory.
Synthesis of F-127' and preparation of HLM-encapsulated FAB hydrogel The synthesis of F-127' and the FAB hydrogel preparation were as previously described [20] . Briefly, F-127', a triblock copolymer, poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) (PEO99-PPO65-PEO99), was derived at both ends of the F127 polymer using acryloyl chloride to generate double bonds. The FAB hydrogel system was prepared using Acr-Bis solution, F127', APS, TEMED and PBS.
The hydrogel still had a thermo-sensitive property such that the polymer chain presented a diastolic state at 4 °C and a systolic state at 37 °C. The prepared FAB hydrogel was immersed in an HLM solution for 48 h at 4 °C before metabolic tests.
Liquid chromatography-tandem mass spectrometry method Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was conducted using an Agilent 1200 series HPLC system (Agilent Technologies, Waldbronn, Germany) coupled to an API 4000 Q Trap mass spectrometer (AB Sciex, Darmstadt, Germany) equipped with an API electrospray ionization (ESI) source.
The chromatography separation was performed on an Agi--lent Technologies, Waldbronn, Germany). The column temperature was maintained at 30 °C. The mobile phase consisted of (A) methanol + 0.2% acetic acid and (B) water + 0.2% acetic The ESI source was operated in negative ionization mode with an ion spray voltage at 4.5 kV. The source temperature was set to 500 °C. Multiple reaction monitoring (MRM) was performed for each sample. The ion transitions were mass-tocharge ratios of (m/z) 269.1 to 169.8 for tolbutamide, 285.0 to 185.8 for 4-hydroxytolbutamide and 178.1 to 148.8 for phenacetin, which was used as the internal standard. All data were analyzed using Analyst software, version 1.6.
Construction of the Bio-PK metabolic system
The Bio-PK metabolic system consisted of a peristaltic pump and an incubation system, tightly connected by a recirculation pipeline. HLMs encapsulated in the FAB hydrogel were placed in the incubation system. Substrate and NADPH were -tem was placed in a thermostatic metal bath. A microdialysis sampling technique was used to obtain the free concentration levels of drugs in hydrogels. A schematic of the Bio-PK system is shown in Figure 1 .
Microdialysis sampling
Microdialysis sampling techniques were integrated into the Bio-PK system to better obtain samples from the FAB hydrogels in real time. The microdialysis systems consisted of a microdialysis syringe pump (CMA/400, CMA, Stockholm, Sweden) and microdialysis probes. The dialysis probes (2 mm in length) have a molecular weight cut-off of 6 kDa (Microbiotech/se AB, Stockholm, Sweden). The substance used as the membrane material was PES (polyether sulphone). The microdialysis probe was inserted into the FAB hydrogel. Thereafter, delivery of the perfusion solution. The perfusate was passed entered the probe through the inlet tubing at a flow rate of through the outlet tubing, collected in a microtube and analyzed by LC-MS/MS.
Recovery assessment of microdialysis probes
The recovery for the microdialysis probe was determined using the no net flux method (NNF) [23] [24] [25] . The microdialysis probe was inserted into the FAB hydrogel from the incubation system of the Bio-PK system at 37 °C containing tolbutamide Flow rate for the Bio-PK metabolic system -tem, different flow rates were set to examine the release of microsomes from the FAB hydrogel and the production of metabolites.
tration of 0.5 mg/mL) were placed in the incubation system Figure 1 . Schematic of the Bio-PK system, consisting of a peristaltic pump, incubation systems and microdialysis systems. HLMs encapsulated in the FAB hydrogel were placed in the incubation system, which was placed in a thermostatic metal bath. The microdialysis system consisted of a microdialysis syringe pump and microdialysis probes.
protein quantitation using the BCA Protein Assay Kit. and 1 mmol/L NADPH were added to the same incubamL/min, 10 mL/min, 20 mL/min or 40 mL/min.
Metabolism of tolbutamide in the Bio-PK metabolic system Following the above description to construct the Bio-PK metawas immersed in HLMs for 48 h at 4 °C and was immediately mixed with PBS buffer containing tolbutamide and NADPH (1 incubation system was preincubated to 37 °C for 5 min in a thermostatic metal bath. The cyclic reactions were initiated with the addition of tolbutamide stock solutions (50, 100 and and maintained at 37 °C for 4 h. Samples of FAB hydrogel and 20, 40, 60, 80, 100, 120, 180, and 240 min. The samples of circontaining the internal standard (IS; phenacetin) and mixed for 2 min on a vortex mixer to terminate the reaction. The solution was centrifuged at 138 000×g for 10 min. The supernatant was transferred to a separate container for LC-MS/MS analysis. The dialysate samples from the FAB hydrogel were directly transferred to microtubes and analyzed by LC-MS/ MS within 48 h.
Mathematical model
Based on the circulating perfusion and mass balance of the Bio-PK system, a mathematical model was developed to describe the above dynamic process and was fitted to the clearance (CL g ) in FAB hydrogel using MATLAB (MathWorks, Inc, Natick, MA, USA). The model considers factors such as diffusion in the FAB hydrogels, the interchange between the and dynamic circulation. The in vitro intrinsic clearance (CL int ) in human is based on the assumption that HLMs per mass unit have the same metabolic capacity. A scheme of the mathematical model is shown in Figure 2 . The relevant formula is as follows:
where C m and C g are the concentration and V m and V g the volume of substrate in the circular medium and FAB hydrogel, respectively; C u is the substrate concentration that came from the hydrogel due to circulation; and the amount of metabolites is expressed by AMTB. Q is the flow rate of the peristaltic pump; D is the diffusion coefficient; f m is the crossover proportion from one end of the pipe into the 1 is the time from one end to the other in the 2 is the migration time in the gel.
PBPK model development
To better verify the Bio-PK system, a PBPK model was develSimcyp™ population-based ADME simulator (V15; Simcyp integrating the in silico and in vitro data of the drug in healthy volunteer population databases from the Simcyp simulator. The Monte Carlo method allows the random generation of a unique set of physiological parameters for each virtual subject, such as anatomic, demographic, and tissue-specific parameters. The variation in each variable was generated by random sampling of each variable within its defined distribution for each simulated virtual subject. The default trial designed by Simcyp was selected to build the model for tolbutamide. A virtual population of 100 healthy volunteers (10 trials with 10 subjects each), aged 20-50 years with a female/male ratio of 0.5, was used to simulate PK following single oral doses of 500 mg of tolbutamide.
A minimal PBPK distribution model with tissue partition coefficients was predicted by the Rodgers method [26] , and a -tion and absorption. The elimination process was characterized by the intrinsic clearance of CYP2C9 and by kidney clearance.
The accuracy of the PBPK model was assessed by compar- ing the ratio between the predicted and observed pharmacokinetic parameters (fold error), together with visual inspection. If observed>predicted, the fold error=observed/predicted; otherwise, fold error=predicted/observed. A model with a fold error of less than two is generally considered a precise model [27] [28] [29] [30] [31] .
Results
In vitro relative recovery of probes
The in vitro recoveries of probes for tolbutamide and 4-hydroxytolbutamide are shown in Table 1 . The actual concentration of tolbutamide and 4-hydroxytolbutamide in the FAB hydrogel could be corrected by an average recovery of 23.74% and 33.46%, respectively.
The diffusion coefficients of tolbutamide from the medium -FAB hydrogel. Following the addition of drug, tolbutamide is rapidly diffused into the FAB hydrogel due to the leakage effect between the hydrogel and the medium; equilibrium was reached after 70 min as the reaction progressed. Therefore, mL/min.
Flow rate for the Bio-PK metabolic system The release of microsomal protein from the FAB hydrogel was Data in the control group indicate that the release of microsomal protein from the FAB hydrogel is in a static state.
With the increase in flow rate, the release of microsomal protein from the FAB hydrogel showed a tendency to increase, indicating that it was gradually washed out of the hydrogel.
was consistent with that of the control group. The concentraminutes and then immediately reached the plateau stage, indicating that the microsomal proteins are firmly locked inside the FAB hydrogel and remain stable for a long period. However, when the flow rate was above 21 mL/min, the release of microsomes was higher than in the control group. With out of the hydrogel gradually advanced. The microsomes washed out of the hydrogel after approximately 12 h at 42 -- Tolbutamide metabolism in the Bio-PK metabolic system After successful construction of the Bio-PK metabolic system, various concentrations of tolbutamide were placed in the system for circulating incubation. The related results are shown in Figures 6, 7 and 8 . In the Bio-PK system, the production of 4-hydroxytolbutamide consistently increased over time and was certainly correlated with the concentration of the substrate. As the reaction progressed, the amount of tolbutamide the saturation level. The volume of the FAB hydrogel was small, resulting in less impact on the substrate concentration in the circulating fluid after the substrate entered the FAB hydrogel over time. Therefore, the concentration of tolbutaabove data will be applied to the mathematical model to fit tolbutamide clearance.
Mathematical model
To better describe the convection-diffusion-reaction characteristics inside the Bio-PK system, a mathematical model was developed using MATLAB by optimizing the discrete model of the parameter values, considering the experimental data and assuming a relative error model. In this model, CL g is the intrinsic substrate clearance in the FAB hydrogel. Based on the metabolism of tolbutamide in the Bio-PK metabolic system, CL g Thus, the corresponding intrinsic clearance of tolbutamide
PBPK model for tolbutamide
The PBPK model of tolbutamide was built based on the parameters in Table 2 . The simulated PK profiles after oral doses of 500 mg of tolbutamide are shown in Figure 9 . Compared to the intrinsic clearance obtained from the previous can be predicted by integrating the intrinsic clearance of tolbutamide obtained from the Bio-PK system into the PBPK model. The simulated C max , AUC and T max of tolbutamide, based on within 2-fold error of the observed results (C max =33500 ng/mL, T max =4.1 h) [32] ( Table 3 ). The literature and predicted in vivo CL values for tolbutamide are shown in Table 4 . The predicted in vivo CL values for tolbuincubation. The mean in vivo CL of tolbutamide predicted by the PBPK model using the clearance obtained from the Bio-PK system was 1.09 L/h, in good agreement with (< 2-fold error) the observed results (mean CL=0.84 L/h) [33] [34] [35] [36] [37] [38] . However, the predicted mean CL obtained from traditional incubation was 0.38 L/h [39, 40] , indicating that the Bio-PK system can better predict metabolic behavior in vivo and obtain more accurate in Figure 6 . Different concentrations of tolbutamide over time in the FAB hydrogel obtained using the Bio-PK metabolic system; n=3, mean±SD. 
Discussion
Liver metabolism is commonly considered the major determinant in drug discovery and development. Many in vitro drug metabolic studies have already been developed and applied to understand biotransformation. These provide some guidance for the screening and development of drugs, as well as the elucidation of metabolic mechanisms and pathways [9] . However, these methods have disadvantages, resulting in inconsistencies between in vivo and in vitro experiments. A major factor is that they are static systems that do not consider the transport process in the liver.
Based on our previous studies, a dynamic Bio-PK metabolic system that consists of a peristaltic pump and an incubation system containing a rat microsome-encapsulated FAB hydrogel is highly expected to be a new tool for in vitro metabolic study [21, 22] . However, the ultimate goal of drug research is focused on human studies. It is often desirable to estimate clearance in humans from measurements performed in vitro and can more clearly illustrate the dynamic system. Tolbutamide-a classical probe substrate for CYP2C9 based on a representative list of preferred and acceptable in vitro probe substrates recommended by FDA guidance-was chosen as the model drug. Many in vitro and in vivo studies have enabled comparison and validation of the dynamic system. In addition, it has been reported that the drug has a low extraction rate [41, 42] , and most current incubation times are short (approximately 30 min), which affects tolbutamide metabolism. The HLMs encapsulated in the FAB hydrogel can better extend microsomal activity at long incubation times. In the dynamic system, tolbutamide quickly diffused in the hydrogel, the accumulation of metabolite increased linearly with time, the substrate and metabolites were accurately detected, and the The solid lines represent the mean plasma concentrations predicted by integrating various in vitro intrinsic clearances; red, purple, orange and green lines represent the plasma concentration simulated by integration of the intrinsic clearance fitted using the Bio-PK system, whereas blue and pale blue lines represent the integration of the intrinsic clearance obtained from the traditional incubation method [39, 40] . Symbols represent mean observed data [32] . B/P, blood-to-plasma ratio; f u,p , free fraction in plasma; f a , fraction of dose absorbed; k a V ss , steady-state volume of distribution; f u,mic , free fraction in liver microsome; CL int , intrinsic clearance; CL R , renal clearance; Q Gut to the gut; PSA, polar surface area; HBD, hydrogen bond donors. Table 3 . Observed versus predicted PK data (AUC, C max and T max ) of tolbutamide in the PBPK model of tolbutamide study.
CL int
C max (ng/mL) T max (h) References/Comments per milligram) Predicted Observed [32] Predicted Observed [32] Predicted Observed [32] 5 we also sought to further verify whether the system can be applied to and promoted in different species to provide the basis for further optimization and application of the system. In this Bio-PK metabolic system, HLMs were encapsulated in the FAB hydrogel as a metabolic element. To better monitor the drug concentration in the FAB hydrogels in realtime, microdialysis [43] , a semi-invasive sampling technique whose principle is dialysis, was integrated into the Bio-PK system. For analysis of the small sample volumes with low concentrations of analytes frequently present in microdialysis samples [44] , LC-MS/MS was used to measure analyte concentrations in the microdialysates [45] . The free drug is more likely to reach the target organ from the vascular compartment and is considered the pharmacologically active portion. Furthermore, plasma and microsomal protein binding plays an important role in pharmacokinetic processes, especially in the distribution and elimination of drug [46] . The main advantage of microdialysis is to exclude proteins from the microdialysate, which stops enzymatic degradation, terminates microsome reactions, and makes sample preparation redundant. Therefore, all microdialysis characteristics are very suitable for system.
In fact, the dialysis process is not in complete equilibrium, and the concentration of the drug in the dialysate obtained by is mainly the concentration of the drug around the semipermeable membrane of the probe. Thus, the in vitro recovery of the probe was used to calibrate the concentration difference. Microdialysis probe recovery was calibrated using the no-net-flux method. No difference in recovery values was observed for the different concentrations of tolbutamide, indicating that the recoveries from the microdialysis probes in the FAB hydrogel are independent of tolbutamide concentration. The recovery of 4-hydroxytolbutamide in the FAB hydrogel was higher than that of tolbutamide, which may be attributed to the metabolism of xenobiotics. This metabolism usually results in compounds that are more polar than the parent drug (reduction in logD), which tends to increase the affinity for drug perfusate [47] . The perfusate of the microdialysis probe is typically aqueous, such as phosphate buffer (PBS), Ringer's solution and anticoagulant citrate dextrose (ACD solution) [48] . Therefore, microdialysis technology is more suitable for the sampling of polar components, and it is difficult to the high hydrophobic and protein binding components [49, 50] . Thus, it is reasonable to expect that 4-hydroxytolbutamide can more easily pass through the membrane compared to tolbutamide.
is 90 L/h (1.5 L/min). This increases in the fed state to 120 L/h (2 L/min) [51] in vitro studies, it leads to a higher requirement for the pump; importantly, the FAB hydrogel can be easily destroyed, which may easily lead to the loss of enzyme activity. Thus, a suitrate should ensure that the FAB hydrogel is not destroyed hydrogel and remain stable for a long period. The release of HLM protein from the FAB hydrogel under different flow rates shows that the HLMs are substantially encapsulated in 21 mL/min. The formation of metabolites further supports the encapsulation capacity and integrity of the FAB hydrogels. Although the FAB hydrogel remains stable and has good loading capacity at 42 mL/min in the short term, the HLMs will 10 mL/min was used in the Bio-PK metabolic system to study human metabolism.
Quantitative analysis of the liver metabolism reaction was demonstrated by combining a mathematical modeling approach and experimental analysis. These complex dynamic processes for the Bio-PK metabolic system, including diffusion, microsomal protein binding, transport and reaction and the substrate interchange between the FAB hydrogel and the circular medium, were described. However, traditional in vitro systems cannot reproduce this aspect of liver metabolism. A diffusion coefficient, D, is used to calculate the amount of drug in the hydrogel at each time step. Partitioning is be estimated from the experiment. If diffusion is high, the amount of drug that partitions into the hydrogel will be lim--gel. In the dynamic system, tolbutamide quickly diffused in the hydrogel, and its metabolic clearance was far below the PK metabolic system ensures that the FAB hydrogel is intact and well encapsulated for HLMs; thus, f m is assumed to be 1 in the model. An average CL g intrinsic clearance was integrated into a PBPK model to prein vivo clearance in humans.
model were used for a good description of the tolbutamide PK mechanistic tissue composition equation [26] set in Simcyp. This result was in good agreement with the observed results (mean V ss =0.103 L/h) [34] [35] [36] . In human beings, tolbutamide is metabolized almost exclusively by CYP2C9 to hydroxytolbutamide. Clearance of tolbutamide from the body is equal to metabolic clearance plus the renal clearance of unchanged drug [32, 35, 52] . Thus, in the PBPK model, elimination was included in the integration of in vitro intrinsic clearance and renal clearance. Based on the in vitro data and the mechanisms mentioned above, an f e (fraction of total body clearance via renal excretion) of 0.26% and an f m (fraction of substrate clearance due to the PBPK model, which integrated the average intrinsic clearance from the Bio-PK metabolic system. Studies have shown that the f m for tolbutamide is 1 [53] . The urinary excretion of tolbutamide at different times is also reasonably predicted. The predicted cumulative urinary recovery of tolbutamide [54] . The liver plays an important role in the human body and is involved in most of the metabolism and elimination of drugs. On this basis, the system was designed and developed and may be more suitable for a drug whose metabolism mainly occurs in the liver, based on the current research. For drugs metabolized in the intestine or other organs, this system may also achieve simulation and prediction by replacing the corresponding microsomes entrapped in the FAB hydrogels, but this hypothesis still requires further validation. For drugs whose renal elimination and transporters play an important role in disposition or for macromolecular drugs with a limited diffusion rate, the current system may require further optimization and integration of additional mechanisms. In brief, the system tries to better model drug metabolism from the perspective of in vitro dynamics. However, the metabolic behavior of the drug is very complicated, and the system must complicated metabolic mechanism.
In summary, a dynamic in vitro metabolic system based on peristaltic pumps and human liver microsomal encapsulated FAB hydrogel was constructed. The integration and application of microdialysis further improved the system. Compared to the traditional incubation method, more reasonable PK proin vivo clearance were predicted by the PBPK model integrated with the intrinsic clearance obtained from the Bioin the metabolic reaction prediction obtained using the Bio-PK metabolic system, demonstrating the feasibility of applying the dynamic system to screen compounds and to understand the metabolic mechanisms, especially for metabolism involving human study. This novel dynamic system also has the potential to further develop in vitro dynamic drug-drug interaction studies. A reliable in vitro dynamic DDI model in the human is also highly desired. This research provides a basis and support for later development and research.
